FDA advisers question efficacy of Roche’s Polivy in first line LBCL— Amid major restructuring, Novartis CEO Narasimhan’s 2022 pay fell by more than a quarter — Merck KGaA makes its Foundry data tools available for free-- See more on our front page news http://bit.ly/w28kSd #fda #roche #lbcl #restructuring #novartis #ceos #executivepay #merckkgaa #opensource #datatools #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma
#FdA #roche #lbcl #restructuring #novartis #ceos #executivepay #merckkgaa #opensource #datatools #pharma #pharmanews #biotech #biopharma #biotechnology #cafepharma